@sharkbiotech Would present a different scenario and met with lethal force versus negotiation and contact controls due to being outnumbered which we saw today.
$TRIL TTI-621 for hematologic malignancies: a Phase I dose escalation and expansion study Dec 9, 2020
https://t.co/AdCQbNEBsz
Steven M. Horwitz, MD Medical Oncologist
Clinical Expertise
T Cell Lymphomas; Cutaneous (Skin) Lymphomas; Other non-Hodgkin and Hodgkin Lymphomas
@Vanfarra Wonโt know until combo, but going theory is monotherapy would provide greater benefit come combo trials.
ASH didnโt meet the hype factor so TRIL is in the penalty box
@RichardRoma6000 How dare they show a more active drug heading into combos. How dare they disclose they have an experienced panel ready to find the best plan for solid tumors